EXOSC9 and cancer: The low-EXOSC9 target signature, indicating high EXOSC9 activity, was significantly correlated with poor prognosis in adrenocortical carcinoma, lung adenocarcinoma, and pancreatic adenocarcinoma, among various cancers from the TCGA datasets (Fig. 7g–i).